Collaboration combines Novo Nordisk’ s scientific leadership in obesity and cardiometabolic diseases with Septerna’ s expertise in G protein-coupled receptor drug discovery Goal is to develop ...

Danish pharmaceutical company Novo Nordisk has signed a collaboration deal with U.S. biotech Septerna that will see the two companies develop pills to treat obesity, type 2 diabetes and other ...

Novo Nordisk and Septerna will jointly initiate four preclinical development programmes, targeting well-established metabolic receptors for glucagon-like peptide 1 (GLP-1), ...

Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills. Novo’s weight-loss drugs are administered by injection and a pill version would be more convenient for patients, ...

Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and ...

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Septerna (SEPN) for obesity pills — the latest in a series of moves by the Danish drugmaker as it hopes to ...

Danish drug maker Novo Nordisk (NVO) on Tuesday announced an exclusive global collaboration and license agreement with U.S.-based Septerna, Inc. (SEPN) to discover, develop, and commercialise oral ...

Collaboration combines Novo Nordisk’s scientific leadership in obesity and cardiometabolic diseases with Septerna’s expertise in G protein-coupled receptor (GPCR) drug discovery Goal is to develop ...

As competition continues to intensify in the obesity treatment market, Novo Nordisk has struck a collaboration and licencing deal worth up to $2.2bn with the US-based biotech Septerna. The ...